Durvalumab-Induced Immune Thrombocytopenia in Patients with Advanced Cholangiocarcinoma Undergoing Yttrium-90 Radioembolization

Introduction: Immune thrombocytopenia (ITP) secondary to durvalumab, a programmed cell death ligand 1 inhibitor, is a rare but clinically significant immune-related adverse event. Herein, we present 2 patients with cholangiocarcinoma who developed ITP immediately post-yttrium-90 radioembolization (Y...

Descrición completa

Detalles Bibliográficos

Principais autores:	Maaz Khan Afghan, Areeb Lutfi, Fatima Qadri, Sahrish Khan, Sana Javaid, Brian Michael Currie, Juan Pablo Rocca, Benjamin Samstein, Erika Hissong, Pashtoon Murtaza Kasi
Formato:	Artigo
Idioma:	Inglês
Publicado:	Karger Publishers 2024-10-01
Series:	Case Reports in Oncology
Assuntos:	cholangiocarcinoma durvalumab immune thrombocytopenia yttrium-90
Acceso en liña:	https://beta.karger.com/Article/FullText/541550
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!